These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39084211)

  • 1. Inflammasome-Inhibiting Nanoligomers Are Neuroprotective against Space-Induced Pathology in Healthy and Diseased Three-Dimensional Human Motor and Prefrontal Cortex Brain Organoids.
    Sharma S; Gilberto VS; Rask J; Chatterjee A; Nagpal P
    ACS Chem Neurosci; 2024 Aug; 15(16):3009-3021. PubMed ID: 39084211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted-Neuroinflammation Mitigation Using Inflammasome-Inhibiting Nanoligomers is Therapeutic in an Experimental Autoimmune Encephalomyelitis Mouse Model.
    Sharma S; Risen S; Gilberto VS; Boland S; Chatterjee A; Moreno JA; Nagpal P
    ACS Chem Neurosci; 2024 Apr; 15(7):1596-1608. PubMed ID: 38526238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.
    Montalbano M; McAllen S; Cascio FL; Sengupta U; Garcia S; Bhatt N; Ellsworth A; Heidelman EA; Johnson OD; Doskocil S; Kayed R
    Neurobiol Dis; 2020 Dec; 146():105130. PubMed ID: 33065281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroanatomical Quantitative Proteomics Reveals Common Pathogenic Biological Routes between Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).
    Iridoy MO; Zubiri I; Zelaya MV; Martinez L; Ausín K; Lachen-Montes M; Santamaría E; Fernandez-Irigoyen J; Jericó I
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
    Kalmar B; Lu CH; Greensmith L
    Pharmacol Ther; 2014 Jan; 141(1):40-54. PubMed ID: 23978556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis.
    Palomo V; Tosat-Bitrian C; Nozal V; Nagaraj S; Martin-Requero A; Martinez A
    ACS Chem Neurosci; 2019 Mar; 10(3):1183-1196. PubMed ID: 30785719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss.
    White MA; Lin Z; Kim E; Henstridge CM; Pena Altamira E; Hunt CK; Burchill E; Callaghan I; Loreto A; Brown-Wright H; Mead R; Simmons C; Cash D; Coleman MP; Sreedharan J
    Acta Neuropathol Commun; 2019 Oct; 7(1):166. PubMed ID: 31661035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.
    Afroz T; Chevalier E; Audrain M; Dumayne C; Ziehm T; Moser R; Egesipe AL; Mottier L; Ratnam M; Neumann M; Havas D; Ollier R; Piorkowska K; Chauhan M; Silva AB; Thapa S; Stöhr J; Bavdek A; Eligert V; Adolfsson O; Nelson PT; Porta S; Lee VM; Pfeifer A; Kosco-Vilbois M; Seredenina T
    Neurobiol Dis; 2023 Apr; 179():106050. PubMed ID: 36809847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammasome-Mediated Neuronal-Microglial Crosstalk: a Therapeutic Substrate for the Familial C9orf72 Variant of Frontotemporal Dementia/Amyotrophic Lateral Sclerosis.
    Trageser KJ; Yang EJ; Smith C; Iban-Arias R; Oguchi T; Sebastian-Valverde M; Iqbal UH; Wu H; Estill M; Al Rahim M; Raval U; Herman FJ; Zhang YJ; Petrucelli L; Pasinetti GM
    Mol Neurobiol; 2023 Jul; 60(7):4004-4016. PubMed ID: 37010807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-amyloid triggers ALS-associated TDP-43 pathology in AD models.
    Herman AM; Khandelwal PJ; Stanczyk BB; Rebeck GW; Moussa CE
    Brain Res; 2011 Apr; 1386():191-9. PubMed ID: 21376022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating ALS-Related Amyloidogenic TDP-43
    Laos V; Bishop D; Lang CA; Marsh NM; Cantrell KL; Buratto SK; Singh AK; Bowers MT
    Biochemistry; 2020 Feb; 59(4):499-508. PubMed ID: 31846303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders.
    Bourbouli M; Rentzos M; Bougea A; Zouvelou V; Constantinides VC; Zaganas I; Evdokimidis I; Kapaki E; Paraskevas GP
    Dement Geriatr Cogn Disord; 2017; 44(3-4):144-152. PubMed ID: 28848086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traumatic brain injury induces TDP-43 mislocalization and neurodegenerative effects in tissue distal to the primary injury site in a non-transgenic mouse.
    Bjorklund GR; Wong J; Brafman D; Bowser R; Stabenfeldt SE
    Acta Neuropathol Commun; 2023 Aug; 11(1):137. PubMed ID: 37608352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice.
    McCann EP; Fifita JA; Grima N; Galper J; Mehta P; Freckleton SE; Zhang KY; Henden L; Hogan AL; Chan Moi Fat S; Wu SS; Jagaraj CJ; Berning BA; Williams KL; Twine NA; Bauer D; Piguet O; Hodges J; Kwok JBJ; Halliday GM; Kiernan MC; Atkin J; Rowe DB; Nicholson GA; Walker AK; Blair IP; Yang S
    J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):162-171. PubMed ID: 31690696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.
    Murray ME; DeJesus-Hernandez M; Rutherford NJ; Baker M; Duara R; Graff-Radford NR; Wszolek ZK; Ferman TJ; Josephs KA; Boylan KB; Rademakers R; Dickson DW
    Acta Neuropathol; 2011 Dec; 122(6):673-90. PubMed ID: 22083254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammasome assembly in neurodegenerative diseases.
    Singh J; Habean ML; Panicker N
    Trends Neurosci; 2023 Oct; 46(10):814-831. PubMed ID: 37633753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
    Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
    Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and meta-analysis of human transcriptomics reveals neuroinflammation, deficient energy metabolism, and proteostasis failure across neurodegeneration.
    Noori A; Mezlini AM; Hyman BT; Serrano-Pozo A; Das S
    Neurobiol Dis; 2021 Feb; 149():105225. PubMed ID: 33347974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling neurodegenerative diseases with cerebral organoids and other three-dimensional culture systems: focus on Alzheimer's disease.
    Venkataraman L; Fair SR; McElroy CA; Hester ME; Fu H
    Stem Cell Rev Rep; 2022 Feb; 18(2):696-717. PubMed ID: 33180261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics analysis of prefrontal cortex of Alzheimer's disease patients revealed dysregulated proteins in the disease and novel proteins associated with amyloid-β pathology.
    Montero-Calle A; Coronel R; Garranzo-Asensio M; Solís-Fernández G; Rábano A; de Los Ríos V; Fernández-Aceñero MJ; Mendes ML; Martínez-Useros J; Megías D; Moreno-Casbas MT; Peláez-García A; Liste I; Barderas R
    Cell Mol Life Sci; 2023 May; 80(6):141. PubMed ID: 37149819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.